Monograph
B01AC07 - Dipyridamole |
Not porphyrinogenic |
NP |
Rationale
No CYP-interactions. Three references consider it safe.
Chemical description
Platelet inhibitor administered as tablets in a dose of 200 mg, Maximal plasma levl is 2.6 ug/mL. In main parts excreted unmetabolized in faeces. Metabolism takes place by conjugation with glucuronic acid. South African list: Use. French list: Authorized. Michael Moore’s list: safe. C.Andersson; patient reports: tolerated (n=1)
IPNet drug reports
Uneventful use reported in 1 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Dipyridamol · Persantin 
Persantin 
Attia · Dipyridamole · Ofcram PR · Persantin · Persantin Retard · Pyridantin · Trolactin 
Dipyridamol · Persantin · Pyranistole 
Aponova · Dipyridamol · Persantin 
Persantin 
Persantin
© NAPOS 2025